Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 78 entries
Sorted by: Best Match Show Resources per page
Using the Intended–Enacted–Experienced Curriculum Model to Map the Vision and Change Core Competencies in Undergraduate Biology Programs and Courses

Asset based approaches STEM training

Clemmons AW, Donovan DA.
GSID: AoTkdcpvZooJ
AW Clemmons, DA Donovan… - … Sciences Education, 2022 - Am Soc Cell Biol

… social and racial injustice that exists in STEM, including existing Science & Society learning … We felt that identification of these differences in interpretation was an asset of our approach, …

Cite
Clemmons, A. W., Donovan, D. A., Theobald, E. J., & Crowe, A. J. (2022). Using the intended–enacted–experienced curriculum model to map the Vision and Change core competencies in undergraduate biology programs and courses. CBE—Life Sciences Education, 21(1), ar6.
Clemmons, Alexa W., et al. "Using the intended–enacted–experienced curriculum model to map the Vision and Change core competencies in undergraduate biology programs and courses." CBE—Life Sciences Education 21.1 (2022): ar6.
Copy Download .nbib Format: MLA
BioSkills guide

Undergraduate training programs stem

Clemmons A, Crowe A, Timbrook J.
GSID: fcnF8nd46I0J
A Clemmons, J Timbrook, J Herron, A Crowe - 2020 - qubeshub.org

… To excel in modern STEM careers, biology majors need training in a range of transferrable skills, yet skills training is often a relatively underdeveloped facet of the undergraduate …

Cite
Clemmons, A., Timbrook, J., Herron, J., & Crowe, A. (2020). BioSkills guide.
Clemmons, Alexa, et al. "BioSkills guide." (2020).
Copy Download .nbib Format: MLA
Inhibiting system x.

Molecular & cellular oncology

Clemons NJ, Liu DS, Duong CP, Phillips WA.
PMID: 29057306
Mol Cell Oncol. 2017 Jul 05;4(5):e1344757. doi: 10.1080/23723556.2017.1344757. eCollection 2017.

Effective therapeutic strategies to target mutant tumor protein p53 (TP53, best known as p53) cancers remain an unmet medical need. We found that mutant p53 impairs the function of nuclear factor (erythroid-derived 2)-like 2 (NFE2L2, commonly known as NRF2),...

Cite
Clemons NJ, Liu DS, Duong CP, et al. Inhibiting system x. Mol Cell Oncol. 2017;4(5):e1344757doi: 10.1080/23723556.2017.1344757.
Clemons, N. J., Liu, D. S., Duong, C. P., & Phillips, W. A. (2017). Inhibiting system x. Molecular & cellular oncology, 4(5), e1344757. https://doi.org/10.1080/23723556.2017.1344757
Clemons, Nicholas J, et al. "Inhibiting system x." Molecular & cellular oncology vol. 4,5 (2017): e1344757. doi: https://doi.org/10.1080/23723556.2017.1344757
Clemons NJ, Liu DS, Duong CP, Phillips WA. Inhibiting system x. Mol Cell Oncol. 2017 Jul 05;4(5):e1344757. doi: 10.1080/23723556.2017.1344757. eCollection 2017. PMID: 29057306; PMCID: PMC5644480.
Copy Download .nbib Format: NLM
Growth Hormone Research Society perspective on biomarkers of GH action in children and adults.

Endocrine connections

Johannsson G, Bidlingmaier M, Biller BMK, Boguszewski M, Casanueva FF, Chanson P, Clayton PE, Choong CS, Clemmons D, Dattani M, Frystyk J, Ho K, Hoffman AR, Horikawa R, Juul A, Kopchick JJ, Luo X, Neggers S, Netchine I, Olsson DS, Radovick S, Rosenfeld R, Ross RJ, Schilbach K, Solberg P, Strasburger C, Trainer P, Yuen KCJ, Wickstrom K, Jorgensen JOL.
PMID: 29483159
Endocr Connect. 2018 Mar;7(3):R126-R134. doi: 10.1530/EC-18-0047. Epub 2018 Feb 26.

OBJECTIVE: The Growth Hormone Research Society (GRS) convened a Workshop in 2017 to evaluate clinical endpoints, surrogate endpoints and biomarkers during GH treatment of children and adults and in patients with acromegaly.PARTICIPANTS: GRS invited 34 international experts including clinicians,...

Cite
Johannsson G, Bidlingmaier M, Biller BMK, et al. Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocr Connect. 2018;7(3):R126-R134doi: 10.1530/EC-18-0047.
Johannsson, G., Bidlingmaier, M., Biller, B. M. K., Boguszewski, M., Casanueva, F. F., Chanson, P., Clayton, P. E., Choong, C. S., Clemmons, D., Dattani, M., Frystyk, J., Ho, K., Hoffman, A. R., Horikawa, R., Juul, A., Kopchick, J. J., Luo, X., Neggers, S., Netchine, I., Olsson, D. S., Radovick, S., Rosenfeld, R., Ross, R. J., Schilbach, K., Solberg, P., Strasburger, C., Trainer, P., Yuen, K. C. J., Wickstrom, K., Jorgensen, J. O. L. (2018). Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocrine connections, 7(3), R126-R134. https://doi.org/10.1530/EC-18-0047
Johannsson, Gudmundur, et al. "Growth Hormone Research Society perspective on biomarkers of GH action in children and adults." Endocrine connections vol. 7,3 (2018): R126-R134. doi: https://doi.org/10.1530/EC-18-0047
Johannsson G, Bidlingmaier M, Biller BMK, Boguszewski M, Casanueva FF, Chanson P, Clayton PE, Choong CS, Clemmons D, Dattani M, Frystyk J, Ho K, Hoffman AR, Horikawa R, Juul A, Kopchick JJ, Luo X, Neggers S, Netchine I, Olsson DS, Radovick S, Rosenfeld R, Ross RJ, Schilbach K, Solberg P, Strasburger C, Trainer P, Yuen KCJ, Wickstrom K, Jorgensen JOL. Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocr Connect. 2018 Mar;7(3):R126-R134. doi: 10.1530/EC-18-0047. Epub 2018 Feb 26. PMID: 29483159; PMCID: PMC5868631.
Copy Download .nbib Format: NLM
Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia.

Journal of the advanced practitioner in oncology

Evans SS, Clemmons AB.
PMID: 26705497
J Adv Pract Oncol. 2015 Jul-Aug;6(4):370-4. doi: 10.6004/jadpro.2015.6.4.7. Epub 2015 Jul 01.

No abstract available.

Cite
Evans SS, Clemmons AB. Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia. J Adv Pract Oncol. 2015;6(4):370-4doi: 10.6004/jadpro.2015.6.4.7.
Evans, S. S., & Clemmons, A. B. (2015). Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia. Journal of the advanced practitioner in oncology, 6(4), 370-4. https://doi.org/10.6004/jadpro.2015.6.4.7
Evans, Sarah S, and Clemmons, Amber B. "Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia." Journal of the advanced practitioner in oncology vol. 6,4 (2015): 370-4. doi: https://doi.org/10.6004/jadpro.2015.6.4.7
Evans SS, Clemmons AB. Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia. J Adv Pract Oncol. 2015 Jul-Aug;6(4):370-4. doi: 10.6004/jadpro.2015.6.4.7. Epub 2015 Jul 01. PMID: 26705497; PMCID: PMC4677809.
Copy Download .nbib Format: NLM
Quantitative historadiography: procedures and application.

Experimental cell research

CLEMMONS JJ.
PMID: 13490405
Exp Cell Res. 1957;13:172-92.

No abstract available.

Cite
CLEMMONS JJ. Quantitative historadiography: procedures and application. Exp Cell Res. 1957;13:172-92
CLEMMONS, J. J. (1957). Quantitative historadiography: procedures and application. Experimental cell research, 13172-92.
CLEMMONS, J J. "Quantitative historadiography: procedures and application." Experimental cell research vol. 13 (1957): 172-92.
CLEMMONS JJ. Quantitative historadiography: procedures and application. Exp Cell Res. 1957;13:172-92. PMID: 13490405.
Copy Download .nbib Format: NLM
Regularization of RIF blind image deconvolution.

IEEE transactions on image processing : a publication of the IEEE Signal Processing Society

Ng MK, Plemmons RJ, Qiao S.
PMID: 18255482
IEEE Trans Image Process. 2000;9(6):1130-4. doi: 10.1109/83.846254.

Blind image restoration is the process of estimating both the true image and the blur from the degraded image, using only partial information about degradation sources and the imaging system. Our main interest concerns optical image enhancement, where the...

Cite
Ng MK, Plemmons RJ, Qiao S. Regularization of RIF blind image deconvolution. IEEE Trans Image Process. 2000;9(6):1130-4doi: 10.1109/83.846254.
Ng, M. K., Plemmons, R. J., & Qiao, S. (2000). Regularization of RIF blind image deconvolution. IEEE transactions on image processing : a publication of the IEEE Signal Processing Society, 9(6), 1130-4. https://doi.org/10.1109/83.846254
Ng, M K, et al. "Regularization of RIF blind image deconvolution." IEEE transactions on image processing : a publication of the IEEE Signal Processing Society vol. 9,6 (2000): 1130-4. doi: https://doi.org/10.1109/83.846254
Ng MK, Plemmons RJ, Qiao S. Regularization of RIF blind image deconvolution. IEEE Trans Image Process. 2000;9(6):1130-4. doi: 10.1109/83.846254. PMID: 18255482.
Copy Download .nbib Format: NLM
Regulatory Actions of Insulin-like Growth Factor-binding Proteins.

Trends in endocrinology and metabolism: TEM

Rechler MM, Clemmons DR.
PMID: 18406262
Trends Endocrinol Metab. 1998 Jul;9(5):176-83. doi: 10.1016/s1043-2760(98)00047-2.

The six insulin-like growth factor-binding proteins (IGFBPs) are important regulators of insulin-like growth factor (IGF) action. Circulating high molecular weight complexes that contain IGF and IGFBP-3 restrict IGF bioavailability, and excess IGFBPs inhibit IGF action by forming biologically inactive...

Cite
Rechler MM, Clemmons DR. Regulatory Actions of Insulin-like Growth Factor-binding Proteins. Trends Endocrinol Metab. 1998;9(5):176-83doi: 10.1016/s1043-2760(98)00047-2.
Rechler, M. M., & Clemmons, D. R. (1998). Regulatory Actions of Insulin-like Growth Factor-binding Proteins. Trends in endocrinology and metabolism: TEM, 9(5), 176-83. https://doi.org/10.1016/s1043-2760(98)00047-2
Rechler, M M, and Clemmons, D R. "Regulatory Actions of Insulin-like Growth Factor-binding Proteins." Trends in endocrinology and metabolism: TEM vol. 9,5 (1998): 176-83. doi: https://doi.org/10.1016/s1043-2760(98)00047-2
Rechler MM, Clemmons DR. Regulatory Actions of Insulin-like Growth Factor-binding Proteins. Trends Endocrinol Metab. 1998 Jul;9(5):176-83. doi: 10.1016/s1043-2760(98)00047-2. PMID: 18406262.
Copy Download .nbib Format: NLM
Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block?.

Future oncology (London, England)

Bouganim N, Clemons MJ.
PMID: 21417901
Future Oncol. 2011 Mar;7(3):381-3. doi: 10.2217/fon.10.192.

Stopeck AT, Lipton A, Body JJ et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. Clin. Oncol. 28(35), 5132-5139 (2010). Bone is the most common...

Cite
Bouganim N, Clemons MJ. Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block?. Future Oncol. 2011;7(3):381-3doi: 10.2217/fon.10.192.
Bouganim, N., & Clemons, M. J. (2011). Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block?. Future oncology (London, England), 7(3), 381-3. https://doi.org/10.2217/fon.10.192
Bouganim, Nathaniel, and Clemons, Mark J. "Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block?." Future oncology (London, England) vol. 7,3 (2011): 381-3. doi: https://doi.org/10.2217/fon.10.192
Bouganim N, Clemons MJ. Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block?. Future Oncol. 2011 Mar;7(3):381-3. doi: 10.2217/fon.10.192. PMID: 21417901.
Copy Download .nbib Format: NLM
Prolonged Versus Short Infusion Rates of IV Magnesium in Hospitalized General Medicine Patients with Hypomagnesemia.

Hospital pharmacy

Doshi S, Waller J, Clemmons A.
PMID: 31983769
Hosp Pharm. 2020 Feb;55(1):64-68. doi: 10.1177/0018578718817941. Epub 2018 Dec 17.

No abstract available.

Cite
Doshi S, Waller J, Clemmons A. Prolonged Versus Short Infusion Rates of IV Magnesium in Hospitalized General Medicine Patients with Hypomagnesemia. Hosp Pharm. 2018;55(1):64-68doi: 10.1177/0018578718817941.
Doshi, S., Waller, J., & Clemmons, A. (2020). Prolonged Versus Short Infusion Rates of IV Magnesium in Hospitalized General Medicine Patients with Hypomagnesemia. Hospital pharmacy, 55(1), 64-68. https://doi.org/10.1177/0018578718817941
Doshi, Shaily, et al. "Prolonged Versus Short Infusion Rates of IV Magnesium in Hospitalized General Medicine Patients with Hypomagnesemia." Hospital pharmacy vol. 55,1 (2020): 64-68. doi: https://doi.org/10.1177/0018578718817941
Doshi S, Waller J, Clemmons A. Prolonged Versus Short Infusion Rates of IV Magnesium in Hospitalized General Medicine Patients with Hypomagnesemia. Hosp Pharm. 2020 Feb;55(1):64-68. doi: 10.1177/0018578718817941. Epub 2018 Dec 17. PMID: 31983769; PMCID: PMC6961155.
Copy Download .nbib Format: NLM
Descriptive Evaluation of Antibody Responses to SARS-CoV-2 Infection in Plasma and Gingival Crevicular Fluid in a Nursing Home Cohort-Arkansas, June-August 2020.

Infection control and hospital epidemiology

Brown NE, Lyons AK, Schuh AJ, Stumpf MM, Harcourt JL, Tamin A, Rasheed MAU, Mills L, Lester SN, Thornburg NJ, Nguyen K, Costantini V, Vinjé J, Huang JY, Gilbert SE, Gable P, Bollinger S, Sabour S, Beshearse E, Surie D, Biedron C, Gregory CJ, Clemmons NS, Whitaker B, Coughlin MM, Seely KA, Garner K, Gulley T, Haney T, Kothari A, Patil N, Halpin AL, McDonald LC, Kutty PK, Brown AC.
PMID: 34802478
Infect Control Hosp Epidemiol. 2021 Nov 22;1-24. doi: 10.1017/ice.2021.484. Epub 2021 Nov 22.

OBJECTIVE: Characterize and compare SARS-CoV-2-specific immune responses in plasma and gingival crevicular fluid (GCF) from nursing home residents during and after natural infection.DESIGN: Prospective cohort.SETTING: Nursing home.PARTICIPANTS: SARS-CoV-2-infected nursing home residents.METHODS: A convenience sample of 14 SARS-CoV-2-infected nursing home...

Cite
Brown NE, Lyons AK, Schuh AJ, et al. Descriptive Evaluation of Antibody Responses to SARS-CoV-2 Infection in Plasma and Gingival Crevicular Fluid in a Nursing Home Cohort-Arkansas, June-August 2020. Infect Control Hosp Epidemiol. 2021;1-24doi: 10.1017/ice.2021.484.
Brown, N. E., Lyons, A. K., Schuh, A. J., Stumpf, M. M., Harcourt, J. L., Tamin, A., Rasheed, M. A. U., Mills, L., Lester, S. N., Thornburg, N. J., Nguyen, K., Costantini, V., Vinjé, J., Huang, J. Y., Gilbert, S. E., Gable, P., Bollinger, S., Sabour, S., Beshearse, E., Surie, D., Biedron, C., Gregory, C. J., Clemmons, N. S., Whitaker, B., Coughlin, M. M., Seely, K. A., Garner, K., Gulley, T., Haney, T., Kothari, A., Patil, N., Halpin, A. L., McDonald, L. C., Kutty, P. K., & Brown, A. C. (2021). Descriptive Evaluation of Antibody Responses to SARS-CoV-2 Infection in Plasma and Gingival Crevicular Fluid in a Nursing Home Cohort-Arkansas, June-August 2020. Infection control and hospital epidemiology, 1-24. https://doi.org/10.1017/ice.2021.484
Brown, Nicole E, et al. "Descriptive Evaluation of Antibody Responses to SARS-CoV-2 Infection in Plasma and Gingival Crevicular Fluid in a Nursing Home Cohort-Arkansas, June-August 2020." Infection control and hospital epidemiology vol. (2021): 1-24. doi: https://doi.org/10.1017/ice.2021.484
Brown NE, Lyons AK, Schuh AJ, Stumpf MM, Harcourt JL, Tamin A, Rasheed MAU, Mills L, Lester SN, Thornburg NJ, Nguyen K, Costantini V, Vinjé J, Huang JY, Gilbert SE, Gable P, Bollinger S, Sabour S, Beshearse E, Surie D, Biedron C, Gregory CJ, Clemmons NS, Whitaker B, Coughlin MM, Seely KA, Garner K, Gulley T, Haney T, Kothari A, Patil N, Halpin AL, McDonald LC, Kutty PK, Brown AC. Descriptive Evaluation of Antibody Responses to SARS-CoV-2 Infection in Plasma and Gingival Crevicular Fluid in a Nursing Home Cohort-Arkansas, June-August 2020. Infect Control Hosp Epidemiol. 2021 Nov 22;1-24. doi: 10.1017/ice.2021.484. Epub 2021 Nov 22. PMID: 34802478.
Copy Download .nbib Format: NLM
SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than .

Molecular cancer therapeutics

Fujihara KM, Corrales Benitez M, Cabalag CS, Zhang BZ, Ko HS, Liu DS, Simpson KJ, Haupt Y, Lipton L, Haupt S, Phillips WA, Clemons NJ.
PMID: 34315763
Mol Cancer Ther. 2021 Oct;20(10):1858-1867. doi: 10.1158/1535-7163.MCT-21-0067. Epub 2021 Jul 26.

APR-246 (eprenetapopt) is in clinical development with a focus on hematologic malignancies and is promoted as a mutant-p53 reactivation therapy. Currently, the detection of at least one

Cite
Fujihara KM, Corrales Benitez M, Cabalag CS, et al. SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than . Mol Cancer Ther. 2021;20(10):1858-1867doi: 10.1158/1535-7163.MCT-21-0067.
Fujihara, K. M., Corrales Benitez, M., Cabalag, C. S., Zhang, B. Z., Ko, H. S., Liu, D. S., Simpson, K. J., Haupt, Y., Lipton, L., Haupt, S., Phillips, W. A., & Clemons, N. J. (2021). SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than . Molecular cancer therapeutics, 20(10), 1858-1867. https://doi.org/10.1158/1535-7163.MCT-21-0067
Fujihara, Kenji M, et al. "SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than ." Molecular cancer therapeutics vol. 20,10 (2021): 1858-1867. doi: https://doi.org/10.1158/1535-7163.MCT-21-0067
Fujihara KM, Corrales Benitez M, Cabalag CS, Zhang BZ, Ko HS, Liu DS, Simpson KJ, Haupt Y, Lipton L, Haupt S, Phillips WA, Clemons NJ. SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than . Mol Cancer Ther. 2021 Oct;20(10):1858-1867. doi: 10.1158/1535-7163.MCT-21-0067. Epub 2021 Jul 26. PMID: 34315763.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 78 entries